Takeda'S Exkivity Gets Approval In China For Metastatic Lung Cancer After Chemo

Takeda Pharmaceutical Co. Ltd. (TKPHF.PK,TAK) Wednesday announced that Exkivity or mobocertinib has been approved by the National Medical Products Administration of China.

Exkivity is an oral tyrosine kinase inhibitor intended for the treatment of adult patients with locally advanced non-small cell lung cancer with epidermal growth factor receptor Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

The company said the approval is based on the Phase 1/2 trial and has shown clinically meaningful and durable responses in patients.

Lung cancer is the most commonly diagnosed cancer in China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Food and Drug Administration has cleared cultivated chicken developed by GOOD Meat Inc., the cultivated meat division of alternative foods startup Eat Just Inc. This is FDA's second pre-market consultation for a human food made from cultured animal cells after UPSIDE Foods. GOOD Meat is now required to meet Federal requirements including approvals from the US Department of Agriculture. A group of 23 U.S. states attorneys general have asked South Korean car manufacturers Hyundai Motor and Kia Corp. to take action more quickly to solve problems with millions of U.S. vehicles facing theft. The issue is related to the companies' failure to equip vehicles with anti-theft immobilizers, which has been a standard equipment on vehicles sold by other major manufacture El Monte, California-based Mutual Trading Co., Inc. is recalling certain Kagome Sauces citing undeclared soy, a known allergen, the U.S. Food and Drug Administration said. The recall involves 60 fl oz of Kagome Worcester Sauce, 10 fl oz of Kagome Chuno sauce, and 8g of Kagome Take out Tonkatsu Sauce.
Follow RTT